Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | ACR | P10323 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7777016 | 0.95 | NR5A1 (0.54) | TSHRLTA4HNR5A1LMNAGAA | |
| SCHEMBL7001372 | 0.95 | CYP1A2 (0.46) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| SCHEMBL3707532 | 0.95 | NR5A1 (0.54) | TSHRLTA4HNR5A1LMNAGAA | |
| SCHEMBL1020538 | 0.95 | NR5A1 (0.54) | TSHRLTA4HNR5A1LMNAGAA | |
| SCHEMBL9702597 | 0.95 | NR5A1 (0.54) | TSHRLTA4HNR5A1LMNAGAA | |
| SCHEMBL9162002 | 0.95 | NR5A1 (0.54) | TSHRLTA4HNR5A1LMNAGAA | |
| SCHEMBL11848774 | 0.95 | NR5A1 (0.54) | TSHRLTA4HNR5A1LMNAGAA | |
| SCHEMBL991987 | 0.93 | CYP2C9 (0.50) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| SCHEMBL1493053 | 0.90 | CYP3A4 (0.52) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| SCHEMBL10341873 | 0.90 | CYP3A4 (0.52) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-9962398-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2018-05-08 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| EP-2590938-B1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC (CA) | 2017-06-07 | — | — | EP | disclosed |
| EP-2945950-B1 | ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC. (CA) | 2017-01-12 | — | — | US | disclosed |
| EP-3088400-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9463171-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2016-10-11 | — | — | US | disclosed |
| US-4465682-A | Combating pests with substituted 3,6-diphenyl-3,4-dihydro-2H-1,3,5-oxadiazine-2,4-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1984-08-14 | — | — | US | disclosed |
| US-4348394-A | Combating pests with substituted 3,6-diphenyl-3,4-dihydro-2H-1,3,5-oxadiazine-2,4-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
| EP-0014881-B1 | OXADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PESTICIDES | BAYER AG (DE) | 1982-02-17 | — | — | EP | disclosed |
| US-4285946-A | ANOREXIGENIC AGENTS; TREATING DISTURBANCES OF THE METABOLISM OF LIPIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-08-25 | — | — | US | disclosed |
| EP-0014881-A1 | Oxadiazine derivatives, process for their preparation and their use as pesticides | BAYER AG (DE) | 1980-09-03 | — | — | EP | disclosed |
| US-4136180-A | HYPOLIPIDEMIC SUBSTITUTED STYRENESULFONYLUREAS | PFIZER INC. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4088766-A | PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4062960-A | Hypolipidemic alkenesulfonamides | PFIZER INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4001256-A | PROSTAGLANDIN PRODUCTION IN MAMMALS | THE UPJOHN COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3983107-A | ARTERIOSCLEROSIS | PFIZER INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP1A2 4730/4885CYP19A1 3363/4885CYP2C9 4746/4885 |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CYP1A2 3705/4885CYP19A1 3098/4885CYP2C9 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.